Swiss National Bank Acquires 21,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Swiss National Bank lifted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 9.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 240,300 shares of the company's stock after buying an additional 21,000 shares during the quarter. Swiss National Bank owned about 0.13% of BridgeBio Pharma worth $6,594,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Steward Partners Investment Advisory LLC boosted its stake in BridgeBio Pharma by 85.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after acquiring an additional 472 shares in the last quarter. Advisors Asset Management Inc. boosted its position in shares of BridgeBio Pharma by 56.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company's stock worth $117,000 after purchasing an additional 1,645 shares in the last quarter. E Fund Management Co. Ltd. grew its stake in shares of BridgeBio Pharma by 13.8% in the 4th quarter. E Fund Management Co. Ltd. now owns 17,785 shares of the company's stock valued at $488,000 after buying an additional 2,151 shares during the period. Quarry LP grew its stake in shares of BridgeBio Pharma by 33.3% in the 3rd quarter. Quarry LP now owns 10,000 shares of the company's stock valued at $255,000 after buying an additional 2,500 shares during the period. Finally, Arizona State Retirement System increased its position in BridgeBio Pharma by 9.7% in the 4th quarter. Arizona State Retirement System now owns 35,470 shares of the company's stock valued at $973,000 after buying an additional 3,141 shares in the last quarter. Institutional investors own 99.85% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Evercore ISI raised their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the company an "outperform" rating in a research note on Monday, December 23rd. JPMorgan Chase & Co. boosted their price target on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the company an "overweight" rating in a research note on Monday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $95.00 price objective on shares of BridgeBio Pharma in a research note on Friday, February 21st. Scotiabank boosted their target price on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Friday, February 21st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $49.00 price target on shares of BridgeBio Pharma in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $52.90.

Insider Activity

In other news, CFO Brian C. Stephenson sold 68,000 shares of BridgeBio Pharma stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total transaction of $2,467,720.00. Following the completion of the sale, the chief financial officer now directly owns 93,758 shares of the company's stock, valued at approximately $3,402,477.82. The trade was a 42.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Neil Kumar sold 326,932 shares of the company's stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the completion of the transaction, the chief executive officer now owns 5,371,515 shares of the company's stock, valued at $194,932,279.35. This trade represents a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 9,579,739 shares of company stock worth $323,171,901. 24.66% of the stock is currently owned by insiders.

BridgeBio Pharma Stock Down 1.7 %

BridgeBio Pharma stock traded down $0.64 during trading on Wednesday, hitting $36.10. The stock had a trading volume of 1,623,903 shares, compared to its average volume of 2,143,677. The stock's 50 day moving average is $34.17 and its two-hundred day moving average is $29.16. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $39.47. The stock has a market cap of $6.87 billion, a price-to-earnings ratio of -12.67 and a beta of 1.07.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The business had revenue of $5.88 million for the quarter, compared to analyst estimates of $4.04 million. As a group, equities research analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.